Zynerba pharmaceuticals.
Based on 3 Wall Street analysts offering 12 month price targets for Zynerba Pharmaceuticals in the last 3 months. The average price target is $1.11 with a high forecast of $1.11 and a low forecast of $1.11. The average price target represents a -14.62% change from the last price of $1.30. Highest Price Target $1.11. Average Price Target $1.11.
Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 …Sep 27, 2023 · 27 Sep, 2023, 08:00 ET. PLYMOUTH MEETING, Pa. , Sept. 27, 2023 /PRNewswire/ -- In connection with the previously announced merger agreement, Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq ... Prescription medications are a vital element of healthcare for many people in the United States. While it’s not completely clear how pharmaceutical companies determine pricing for many drugs, some of the most expensive medications and treat...Annual Meeting to Reconvene on August 25, 2023 at 9:00 a.m. EDT. Devon, PA, August 8, 2023 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the new date for the adjourned 2023 Annual Meeting of Stockholders (“Annual Meeting ...Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), which works on innovative pharmaceutically produced transdermal cannabinoid therapies for neuropsychiatric disorders, posted results for the third quarter that revealed ample cash on hand, giving the company scope to fund pivotal trials of its flagship product Zygel (ZYN002). As of …
Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome and 22q11.2 deletion syndrome.
Return On Tangible Equity. Current and historical return on investment (ROI) values for Zynerba Pharmaceuticals, Inc. (ZYNE) over the last 10 years. ROI - Return on Investment Historical Data. Date.
Omeros Corp. -5.14%. $183.54M. ZYNE | Complete Zynerba Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Senior Financial Executive with General Management experience and a proven record of… | Learn more about Jim Fickenscher's work experience, education, connections & more by visiting their ...Devon, PA, June 30, 2020 – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced top line results from the 14-week pivotal CONNECT-FX (Clinical study of Cannabidiol (CBD) in Children and Adolescents ...About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders.
May 16, 2022 · Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, and 22q11 ...
DEVON, Pa., December 17, 2020 – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today provided an update on its meeting with the U.S. Food and Drug Administration (FDA) regarding its Fragile X syndrome (FXS ...
Prescription medications are a vital element of healthcare for many people in the United States. While it’s not completely clear how pharmaceutical companies determine pricing for many drugs, some of the most expensive medications and treat...Zynerba Pharmaceuticals – US-Based Clinical Stage Pharmaceutical Company. Zynerba Pharmaceuticals is a US company that specializes in the development and commercialization of patented next ...ZYNERBA PHARMACEUTICALS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Zynerba Pharmaceuticals Inc | A14XCV | ZYNE | US98986X1090.01 Sept 2023 ... Hello Quick question regarding the Zynerba Pharmaceuticals tender offer, if choosing Option1 will I receive cash & shares in Harmony ...Earnings for Zynerba Pharmaceuticals are expected to grow in the coming year, from ($0.84) to ($0.49) per share. Price to Earnings Ratio vs. the Market. The P/E ratio of Zynerba Pharmaceuticals is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Zynerba Pharmaceuticals Inc stock price live 1.300, this page displays NASDAQ ZYNE stock exchange data. View the ZYNE premarket stock price ahead of the market session or assess the after hours quote.Zynerba Pharmaceuticals is dedicated to the development of innovative transdermal cannabinoid treatments for patients with high unmet medical needs using modern drug delivery technology and appropriate regulatory pathways. Zynerba is developing two therapeutic candidates based on proprietary transdermal technologies that, if successfully developed,Warren D. Cooper, MB, BS, BSc, MFPMLead Independent Director. Dr. Warren Cooper has served as a member of our Board since August 2015. Dr. Cooper is a U.K.-trained physician with more than 40 years of experience in the global pharmaceutical industry. Since January 2017, Dr. Cooper has served as Chief Medical Officer of Healthcare Royalty, a ... Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, 22q11.2 deletion syndrome and autism …Harmony's tender offer to acquire all outstanding shares of Zynerba for a purchase price of $1.1059 per share in cash, or $60 million in the aggregate, plus one non-tradeable contingent value ...Zynerba Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 26-0389433 (I.R.S. Employer Identification Number) 80 W. Lancaster Avenue, Suite 300. Devon, PA 19333 (484) 581-7505
EXPLANATORY NOTE . This Registration Statement is being filed for the purpose of registering an additional 1,500,000 shares of common stock, $0.001 par value per share (the “Common Stock”), of Zynerba Pharmaceuticals, Inc. (the “Registrant”) that were added to the shares authorized for issuance under the Zynerba Pharmaceuticals, Inc. Amended …Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of ...
About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.Harmony Biosciences is a U.S. commercial-stage pharmaceutical company dedicated to developing and commercializing innovative therapies for people living with rare neurological disorders who have unmet medical needs. Established by founder Paragon Biosciences LLC, our mission is to positively impact the lives of those living with rare diseases ...Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer (the “Offer”) by Harmony Biosciences Holdings, Inc ...Zynerba Pharmaceuticals, Inc. eps - earnings per share from 2015 to 2023. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.Aug 14, 2023 · Zynerba is a pharmaceutical company focused on the development of synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists of Zygel which is a ... Number of Employees. Zynerba Pharmaceuticals, Inc. number of employees from 2015 to 2023. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Zynerba Pharmaceuticals, Inc. Annual Number of Employees. 2022.
Newsroom HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE New product in …
DEVON, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal …
Return On Tangible Equity. Current and historical return on investment (ROI) values for Zynerba Pharmaceuticals, Inc. (ZYNE) over the last 10 years. ROI - Return on Investment Historical Data. Date.Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 …Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural …Zynerba is a leader in pharmaceutically produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders.Shares of Zynerba Pharmaceuticals ( ZYNE) were crashing 18.3% lower as of 10:48 a.m. EDT on Wednesday after falling as much as 26.5% earlier in the morning. The big plunge came after Zynerba ...Nov 2, 2022 · Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, 22q11.2 deletion syndrome and autism spectrum ... Zynerba is a leader in pharmaceutically produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. Harmony President & CEO Jeffrey M. Dayno, MD, described its lead candidate, Zygel, as a 'portfolio in a product' with the potential to serve 80,000 U.S. patients who are diagnosed with Fragile X syndrome (FXS) and …27 Sep, 2023, 08:00 ET. PLYMOUTH MEETING, Pa. , Sept. 27, 2023 /PRNewswire/ -- In connection with the previously announced merger agreement, Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq ...
General Manager, Zynerba Pharmaceuticals Pty Ltd (Australia) Terry Hurst has served as the General Manager of Zynerba Pharmaceuticals Pty Ltd (Australia) since October 2017. He has 16 years of executive management experience in the early phase clinical trial sector of the biopharmaceutical industry. Mr Hurst has extensive experience in General ... Devon, PA, June 30, 2020 – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced top line results from the 14-week pivotal CONNECT-FX (Clinical study of Cannabidiol (CBD) in Children and Adolescents ...Zynerba Pharmaceuticals, Inc., together with its subsidiary, Zynerba Pharmaceuticals Pty Ltd (collectively, “Zynerba,” the “Company,” or “we”), is a clinical stage specialty pharmaceutical company focused on the development of pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders ...Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, and 22q11 ...Instagram:https://instagram. stock winners todaytrading platform for day tradersbest cheap computer deskbest online banking app Sep 27, 2023 · 27 Sep, 2023, 08:00 ET. PLYMOUTH MEETING, Pa. , Sept. 27, 2023 /PRNewswire/ -- In connection with the previously announced merger agreement, Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq ... synovuaonline day trading classes PLYMOUTH MEETING, PA, October 11, 2023 — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to … tesla stock projections Zynerba Pharmaceuticals has agreed to merge with Harmony Biosciences. Under the proposed transaction, Zynerba shareholders will receive $1.1059 in cash and a non-tradeable contingent value right.Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, 22q11.2 deletion syndrome and autism spectrum ...